GALAPAGOS
Galapagos NV develops medicines for oncology and immunology, primarily in the US and Europe. Their pipeline includes GLPG3667, GLPG5101, GLPG5201, and GLPG5301, all CAR-T product candidates. These products are in various stages of Phase 1/2 trials for different types of cancer. The company has collaboration agreements with Gilead Sciences and AbbVie.
Overview
Strengths
- Price to book ratio (0.63) is lower than the sector mean (24.44).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 25.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 1.0 |